Cost-Effectiveness of Providing the Depression Care for People With Cancer Program to Patients With Prostate Cancer in the United States

Feb 1, 2021, 00:00
10.1016/j.jval.2020.09.008
https://www.valueinhealthjournal.com/article/S1098-3015(20)34412-0/fulltext
Title : Cost-Effectiveness of Providing the Depression Care for People With Cancer Program to Patients With Prostate Cancer in the United States
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)34412-0&doi=10.1016/j.jval.2020.09.008
First page : 216
Section Title : ECONOMIC EVALUATION
Open access? : No
Section Order : 216

Objectives

The Depression Care for People with Cancer program (DCPC) is a cost-effective depression care model for UK patients with cancer. However, DCPC’s cost-effectiveness in the United States is unknown, particularly for patients with prostate cancer in the United States. This study evaluates the health and economic impact of providing DCPC to patients with prostate cancer.

Methods

DCPC was compared with usual care in a mathematical model that simulates depression and its outcomes in a hypothetical cohort of US patients with prostate cancer. DCPC was modeled as a sequential combination of universal depression screening, post-screening evaluations, and first-line combination therapy. Primary outcomes were lifetime direct costs of depression care, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Secondary outcomes included life expectancy, number of depression-free months and lifetime depressive episodes, duration of depressive episodes, cumulative incidence of depression, lifetime depression diagnoses/misdiagnoses, and the cumulative incidence of maintenance therapy for depression. Sensitivity analyses were used to examine uncertainty.

Results

In the base case, DCPC dominated usual care by offering 0.11 more QALYs for $2500 less per patient (from averted misdiagnoses). DCPC also offered 5 extra depression-free months, shorter depressive episodes, and a lower chance of maintenance therapy. DCPC’s trade-offs were a higher cumulative incidence of depression and more lifetime depressive episodes. Life expectancy was identical under usual care and DCPC. Sensitivity analyses indicate that DCPC was almost always preferable to usual care.

Conclusion

Compared with usual care, DCPC may offer more value to US patients with prostate cancer. DCPC should be considered for inclusion in prostate cancer survivorship care guidelines.

Categories :
  • Cost-comparison, Effectiveness, Utility, Benefit Analysis
  • Economic Evaluation
  • Health Service Delivery & Process of Care
  • Mental Health
  • Oncology
  • Specific Diseases & Conditions
  • Treatment Patterns and Guidelines
Tags :
  • antidepressants
  • cost-effectiveness analyses
  • depression
  • economic evaluation
  • prostate cancer
  • psychotherapy
  • screening
Regions :
ViH Article Tags :